Article Contents ::
- 1 The Brand Name PREVENAR Has Generic Salt :: PNEUMOCOCCAL
- 2 PREVENAR Is From Company WYETH Priced :: Rs. 3726.71
- 3 PREVENAR have PNEUMOCOCCAL is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name PREVENAR Has Generic Salt :: PNEUMOCOCCAL
PREVENAR Is From Company WYETH Priced :: Rs. 3726.71
PREVENAR have PNEUMOCOCCAL is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| PNEUMOCOCCAL | VACCINE | Rs. 3726.71 | VACCINE |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / VACCINE |
| PREVENAR | WYETH | N.I. | VACCINE | Rs. 3726.71 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From WYETH :: PREVENAR | PNEUMOCOCCAL | #N/A | #N/A |
Indications for Drugs ::
Prevention of pneumococcal disease
Drug Dose ::
Pneumococcal polysaccharide vaccine (PPSV23) is recommended for all adults 65 years or older. People 2 years through 64 years of age who are at high risk of pneumococcal disease (e.g., those with sickle cell disease, HIV infection, or other immunocompromising conditions) should also receive PPSV23. Primary Immunization: One 0.5 mL inj is sufficient to provide protection against the pneumococcal serotypes contained in the vaccine. Revaccination: One 0.5 mL inj must not be given within 5 years except in very high-risk subjects or patients under immunosuppressive treatment. Administered intramuscularly or subcutaneously only.
Contraindication ::
A known allergy to one of the components of the vaccine. Fever or acute disease or a relapse of a chronic disease: It is preferable to postpone vaccination. Vaccination is not recommended for subjects who have been vaccinated within the previous 3 years, unless indicated otherwise. A confirmed or suspected episode of pneumococcal infection is not a contraindication and vaccination should be considered according to the underlying risk status.
Drug Precautions ::
Use in pregnancy: It should only be used during pregnancy on medical advice.
Drug Side Effects ::
Local Reactions at the Injection Site: Pain, erythema (redness), induration and oedema (swelling). These reactions are mild and transient. Rare reactions eg, Arthus phenomenon (severe local reactions) are reversible without after-effects; they mainly occur in subjects with high initial levels of pneumococcal antibody. Moderate and transient hyperthermia (fever) sometimes >39°C which generally occurs very shortly after vaccination and resolves within 24 hrs. Other General Reactions: Adenopathy (inflammation of the lymph nodes), rashes, arthralgia (pain in the joints) and allergic reactions [urticaria, Quincke’soedema (type of urticaria with sudden swelling of the face and neck), anaphylactoid reactions (severe allergic reaction)], headache, muscle pain, malaise, and fatigue have exceptionally been reported.
Pregnancy category ::
3
Drug Mode of Action ::
S. pneumoniae capsular antigens stimulate active immune response resulting in production of endogenously produced antibodies
Drug Interactions ::
Reduce immune response to Zostavax. Immunosuppressives.
